QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:GLTO

Galecto (GLTO) Stock Forecast, Price & News

$2.39
+0.13 (+5.75%)
(As of 06/6/2023 ET)
Compare
Today's Range
$2.26
$2.41
50-Day Range
$1.68
$2.66
52-Week Range
$1.04
$2.95
Volume
57,183 shs
Average Volume
61,502 shs
Market Capitalization
$61.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

Galecto MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
388.1% Upside
$11.67 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$401,514 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.30) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

414th out of 981 stocks

Pharmaceutical Preparations Industry

199th out of 460 stocks


GLTO stock logo

About Galecto (NASDAQ:GLTO) Stock

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Receive GLTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

GLTO Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
Galecto (GLTO) Gets a Buy from H.C. Wainwright
Orbimed Advisors Now Owns 10.5% of Galecto
See More Headlines

GLTO Price History

GLTO Company Calendar

Last Earnings
3/09/2023
Today
6/06/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLTO
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.67
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+388.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-61,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.41 per share

Miscellaneous

Free Float
22,567,000
Market Cap
$61.35 million
Optionable
Not Optionable
Beta
0.74

Key Executives

  • Dr. Hans T. Schambye M.D. (Age 56)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $735.2k
  • Mr. Jonathan P. Freve CPAMr. Jonathan P. Freve CPA (Age 44)
    CPA, Chief Financial Officer
    Comp: $602.4k
  • Mr. Anders Pedersen (Age 62)
    Chief Operating Officer
    Comp: $540.39k
  • Mr. Ulf J. Nilsson
    Co-Founder
  • Dr. Hakon Leffler
    Co-Founder
  • Prof. Tariq Sethi M.D.
    B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF
  • Mr. Garrett Winslow Esq.Mr. Garrett Winslow Esq. (Age 43)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Prof. Bertil Lindmark M.D. (Age 67)
    Ph.D., Chief Medical Officer
  • Dr. Stephanie Oestreich Ph.D. (Age 48)
    Chief Bus. Officer













GLTO Stock - Frequently Asked Questions

Should I buy or sell Galecto stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLTO shares.
View GLTO analyst ratings
or view top-rated stocks.

What is Galecto's stock price forecast for 2023?

4 analysts have issued 12 month price targets for Galecto's stock. Their GLTO share price forecasts range from $6.00 to $16.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 388.1% from the stock's current price.
View analysts price targets for GLTO
or view top-rated stocks among Wall Street analysts.

How have GLTO shares performed in 2023?

Galecto's stock was trading at $1.15 on January 1st, 2023. Since then, GLTO stock has increased by 107.8% and is now trading at $2.39.
View the best growth stocks for 2023 here
.

When is Galecto's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our GLTO earnings forecast
.

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) announced its quarterly earnings results on Thursday, March, 9th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.02.

What ETF holds Galecto's stock ?

BlackRock Future Health ETF holds 610 shares of GLTO stock, representing 0.02% of its portfolio.

When did Galecto IPO?

(GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Galecto's stock symbol?

Galecto trades on the NASDAQ under the ticker symbol "GLTO."

Who are Galecto's major shareholders?

Galecto's stock is owned by a variety of retail and institutional investors. Top institutional investors include MAI Capital Management (1.00%), Susquehanna International Group LLP (0.25%) and Two Sigma Advisers LP (0.21%). Insiders that own company stock include Bertil Lindmark, Garrett Winslow, Hans T Schambye, Jonathan Freve and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Galecto?

Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galecto's stock price today?

One share of GLTO stock can currently be purchased for approximately $2.39.

How much money does Galecto make?

Galecto (NASDAQ:GLTO) has a market capitalization of $61.35 million. The company earns $-61,620,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How can I contact Galecto?

Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The official website for the company is galecto.com. The company can be reached via phone at 45-7070-5210.

This page (NASDAQ:GLTO) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -